While there is not enough evidence to support the use of PSMA PET/CT as the sole screening test in active surveillance patients, it is possible that PSMA PET/CT may be able to prevent biopsies and more accurately detect prostate cancer than conventional methods in the future. The gene discussed is FOLH1; the disease is Familial prostate cancer.